Significant regulatory advances for lead candidate EB613 streamline Phase 3 clinical development and reduce regulatory hurdles. These 10 stocks could mint the next wave of millionaires › Entera Bio ...

Weight-loss drugs spur debate and open new doors for CU Anschutz researcher studying food/brain relationshipOccasionally ...

JERUSALEM, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key ...

Eli Lilly's orforglipron missed weight loss targets in a Phase 3 trial, but strong Q2 results and raised guidance highlight ...

Stopping prescription weight loss drugs often leads to significant weight regain, according to a large-scale analysis of 11 global studies. Researchers found that although these medications, including ...

A real-world study found that semaglutide prescriptions were associated with improvements in weight, blood pressure, and ...

GLP-1 medications like Ozempic and Zepbound are transforming chronic disease and weight management, with perimenopausal women ...

Weight loss of at least 5% was associated with improvements in PROs among individuals with RMDs taking weight loss medications.

Key Takeaways More than 1 in 10 Americans has tried a GLP-1 drug50- to 64-year-olds report the most useSide effects like ...

A new daily weight loss pill could be available soon – and a recent trial has shown that people taking the drug can shed ...

Doctors from only four medical specialties will be able to write prescriptions for injectable drugs that are used to treat ...